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The Twin Research Registry at SRI International
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The Twin Research Registry (TRR) at SRI International is a community-based registry of twins established
in 1995 by advertising in local media, mainly on radio stations and in newspapers. As of August 2012,
there are 3,120 same- and opposite-sex twins enrolled; 86% are 18 years of age or older (mean age 44.9
years, SD 16.9 years) and 14% less than 18 years of age (mean age 8.9 years, SD 4.5); 67% are female,
and 62% are self-reported monozygotic (MZ). More than 1,375 twins have participated in studies over
the last 15 years in collaboration with the University of California Medical Center in San Francisco, the
University of Texas MD Anderson Cancer Center, and the Stanford University School of Medicine. Each
twin completes a registration form with basic demographic information either online at the TRR Web site
or during a telephone interview. Contact is maintained with members by means of annual newsletters and
birthday cards. The managers of the TRR protect the confidentiality of twin data with established policies;
no information is given to other researchers without prior permission from the twins; and all methods and
procedures are reviewedby an Institutional ReviewBoard. Phenotypes studied thus far include those related
to nicotine metabolism, mutagen sensitivity, pain response before and after administration of an opioid,
and a variety of immunological responses to environmental exposures, including second-hand smoke and
vaccination for seasonal influenza virus and Varicella zoster virus. Twins in the TRR have participated in
studies of complex, clinically relevant phenotypes that would not be feasible to measure in larger samples.
 Keywords: twins, genetics, metabolism, vaccines, immunology
Overview
Investigators within the Center for Health Sciences at SRI
International (formerly known as the Stanford Research
Institute), an independent, not-for-profit research organi-
zation founded in 1946 with headquarters in Menlo Park,
California, have a substantial track record of utilizing the
twin design to determine the relative proportion of envi-
ronmental and genetic variance in survey-based and clin-
ically measured phenotypes. Utilizing twin pairs from the
National Academy of Sciences/National Research Council
(NAS/NRC) World War II Twin Registry (Hrubec & Neel,
1978) and amore intensively studied subset of twins known
as theNHLBI Twin Study (Feinleib et al., 1977), these inves-
tigators and their collaborators published biometric studies
of the heritability of tobacco smoking behaviors (Carmelli
et al., 1992), the co-occurrence of substance use includ-
ing tobacco, alcohol, and caffeine (Swan et al., 1996, 1997),
brain morphology as determined by magnetic resonance
imaging (Carmelli et al., 2002; Lessov-Schlaggar et al., 2012;
Pfefferbaum et al., 2001; Sullivan et al., 2001) and cogni-
tive functioning as assessed by neuropsychological testing
(Lessov-Schlaggar et al., 2007; Swan&Carmelli, 2002; Swan
et al., 1999).
Creation, Growth, and Maintenance of the
Twin Research Registry at SRI Interna-
tional
As a follow-up to our 1992New England Journal ofMedicine
paper on the genetics of ever smoking, smoking quantity,
and smoking cessation (Carmelli et al., 1992), the Twin
Research Registry (TRR) at SRI International was created
to develop a study sample of adult twins to support more
in-depth studies of nicotine dependence and related pheno-
types including nicotine metabolism. California laws per-
taining to the privacy of birth records and Department
of Motor Vehicles files precluded the development of a
population-based registry of adult twins. Therefore, we in-
stead elected to create a community-based registry in the
San Francisco Bay Area and in 1995 initiated an exten-
sive advertising campaign that included 19 newspapers, San
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TABLE 1
Basic Demographics of Participants on the Twin Research Registry at SRI International
Self-reported zygosity Gender
Registered twins Monozygotic Dizygotic Unknown Male Female
Adults 2,683 (86%) 1,769 (66%) 798 (30%) 116 (4%) 844 (30%) 1,839 (70%)
Under 18 437 (14%) 159 (36%) 239 (55%) 39 (9%) 199 (46%) 238 (54%)
Total 3,120 1,928 (62%) 1,037 (33%) 155 (5%) 1,043 (33%) 2,077 (67%)
Francisco Bay Area-wide movie theaters, and AM/FM ra-
dio stations. Within 2.5 years, this campaign resulted in the
enrollment of a total of 1,054 individual twins. A 5-year
anniversary celebration party, held in July 2000, increased
enrollment to 1,765 individual twins. In 2001, the TRR was
expanded to include twins under the age of 18 years. By
2009, as a result of sustained and intensive advertising in
local media and TRRmember referrals, membership in the
TRR increased to 2,700 twins. Table 1 provides a description
of the basic demographics of the sample of over 3,000 twins
currently enrolled in the TRR.
Contact with twins in the TRR is maintained via an-
nual newsletters and birthday cards. The TRR Web site
(http://www.sri.com/twin) is updated periodically and re-
ferrals to the TRR by registered twins are encouraged with
a $25 incentive. The TRR also has a presence on Facebook
and Twitter. All activities related to recruitment, advertis-
ing, and ongoing contact with the twins are reviewed and
approved by the Institutional Review Board of SRI Interna-
tional.
Zygosity Assessment
Originally, twinswere asked to complete a short registration
form consisting of the following questions (Cederlof et al.,
1961; Sarna et al., 1978): (1) ‘As far as you know, are you and
your twin: fraternal, identical or don’t know?’; (2) ‘During
your entire life, how close do you feel that you and your twin
have been compared with your impression of closeness be-
tween ordinary siblings: less close, as close as, somewhat
closer, or much closer than ordinary siblings?’; (3) ‘How
far in miles do you live from your twin now?’ (4) ‘How
frequently do you and your twin get together now: almost
daily, 1–4 times per week, 1–3 times per month, occasion-
ally during the year, less than once per year?’ Responses to
the initial questions were then used to assign preliminary
zygosity status. More recently, a revised questionnaire was
mailed to all registered twins to collect responses to a se-
ries of questions developed at Washington University in St.
Louis to estimate twin zygosity. The classification algorithm
assigns weights to responses to items concerning physical
similarity, whether parents, teachers, or strangers ever mis-
took one twin for the other, whether blood test verification
was ever obtained, and self-reported zygosity (Heath et al.,
2003).
For those twins participating in one of our studies, self-
reported zygosity is confirmedbased on genotyping of short
tandem repeat (STR) regions of genomic DNA (Edwards
et al., 1991) and the twins are notified of the results.We have
learned that this information is an important motivator for
twins to participate in research studies. For those twins who
have indicated in surveys that they have had their zygosity
confirmed by laboratory testing, we have asked that they
send in their results so we can add them to our database. So
far, we have received 39 such reports.
Projects Involving the Twin Research Reg-
istry at SRI International
Since 1998, the TRR at SRI International has supported at
least 10 distinct, funded studies. These studies fall into two
broad categories: those that are focusedondrugmetabolism
and related phenotypes such as subjective effects and de-
pendence and those that are focused on the effects of a
variety of agents that influence the human immunological
response repertoire. Figure 1 provides a timeline for each
study and Table 2 summarizes the phenotypes described in
published papers that have been examined in twin partici-
pants recruited from the TRR.
Studies Focused on Drug Metabolism and
Related Phenotypes
The study ‘Pharmacokinetics of Nicotine in Twins’
(DA011170) involved 139 twin pairs (110 MZ and 29 dizy-
gotic [DZ] pairs) who participated in an in-hospital fixed
dose infusion of radio-labeled nicotine and cotinine pro-
tocol. The pharmacokinetics of nicotine metabolism in
both plasma and urinewere subsequently determined using
techniques developed by Benowitz, Jacob, and colleagues
(Benowitz & Jacob, 1994; Jacob et al., 1988, 1991, 2002).
Data from this study, the world’s largest existing twin study
of nicotine metabolism, have resulted in several reports on
biometric estimates of genetic and environmental contribu-
tions to different aspects of nicotine metabolism (Benowitz
et al., 2008; Conti et al., 2009; Lessov-Schlaggar et al., 2009;
Swan & Lessov-Schlaggar, 2009; Swan et al., 2004, 2005,
2009), as well asmeasured genetic and environmental influ-
ences onmetabolism itself (Al Koudsi et al., 2006; Benowitz,
Lessov-Schlaggar et al., 2006; Benowitz, Swan et al., 2006;
Mwenifumbo et al., 2008).
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TABLE 2
Representative Phenotypes Examined in the Twin Research Registry at SRI International (Published Only)
Project/phenotype
Pharmacokinetics of nicotine in twins
Hepatic — nicotine and cotinine clearance, the conversion of nicotine to cotinine, nicotine metabolic ratio in plasma and urine
Glucuronidation — nicotine-glucuronide/nicotine, cotinine-glucuronide/cotinine, 3 hydroxycotinine-glucuronide/3 hydroxycotinine,
nicotine-glucuronide/nicotine area under the curve, cotinine-glucuronide/cotinine area under the curve
Renal — total clearance nicotine and cotinine, glomerular filtration rate, net secretory/reabsorptive clearance of nicotine and cotinine
Pharmacodynamic — heart rate acceleration and deceleration during and after infusion of a fixed dose of nicotine
Genetic influence on mutagen sensitivity
Cancer susceptibility markers — mutagen sensitivity (mean breaks per cell) in response to bleomycin, benzo(alpha)pyrene diolepoxide,
gamma radiation, 4-nitroquinoline-1-oxide; mitochondrial DNA content
Opioid efficacy in humans
Experimental pain — threshold and tolerance to heat and cold pain before and after infusion of Alfentanil
Nonanalgesic effects — sedation, respiratory depression, nausea, pruritis, positive affective response before and after infusion of Alfentanil
Data from the study described above contributed to the
first and second generations of the project ‘Pharmacokinet-
ics of Nicotine Addiction and Treatment’ (U01DA020830).
In the first generation of this project, DNA samples from
the twin study as well as those from a family study of nico-
tine metabolism (University of California Tobacco-Related
Disease Research Program, 7PT2000-1004) were integrated
with a collection of DNA samples from eight randomized
clinical trials of various smoking cessation treatments for
genotyping or sequencing and analysis of selected pharma-
codynamic and pharmacokinetic loci. Analysis of pharma-
codynamic candidate genes resulted in the identification of
genetic associations (both common and rare variants) with
responsiveness to treatment (Conti et al., 2008; Lee et al.,
2011, 2012; Swan et al., 2011) and with nicotine depen-
dence (Bergen et al., 2009; Falcone et al., 2011; Wessel et
al, 2010). The second generation of this project (ongoing)
will examine the extent to which individual variation in the
nicotinemetabolic ratio (NMR;3’hydroxycotinine/cotinine
ratio) with known heritability (Swan et al., 2009) medi-
ates responsiveness to medications commonly used to treat
nicotine dependence in a randomized trial design (Lerman
et al., 2006; Swan et al., 2010).
Themost recent studies involvingDNAsamples collected
from the original twin study of nicotine metabolism utilize
data from theDMETTM Plus assay fromAffymetrix that was
used to interrogate 1,936 markers at 236 drug metabolizing
and transporter genes for their association with the NMR
in the twin dataset and in the previously mentioned fam-
ily study of nicotine metabolism dataset. The initial work
of collecting and analyzing this genotype data, ‘Metabolic
SNPs andNicotine andCotinineMetabolism inTwo Family
Based Samples’, was funded by a Collaboration Agreement
amongMedcoHealth Solutions, Affymetrix, and SRI Inter-
national (Bergen et al., 2010), and theworkwill be extended
using funding from National Institutes of Health (NIH)
in the project ‘DMET Genes, Nicotine Metabolism, and
Prospective Abstinence’ (DA033813). The initial analysis of
genotype data identified variation at several pharmacoki-
netic genes associated with nicotine metabolism, including
classical genes and genes not previously associated with
nicotine metabolism (Bergen et al., 2010). Future work will
take a unique approach to gene discovery by using anal-
ysis of the two family-based datasets, where associations
identified in the twin dataset (Bergen et al., 2010) are be-
ing confirmed in the family study dataset (Bergen, Javitz
et al., 2012; Bergen, Wacholder et al., 2012). Those single-
nucleotide polymorphism (SNP) associations common to
both datasets will then be examined for their significance in
relation to abstinence outcomes in the previously described
collection of eight clinical trials. This approach should de-
termine in amore rapid fashion those SNPs that have poten-
tial for translation to the clinical setting as biomarkers for
association with nicotine metabolism-related phenotypes
such as cigarettes per day and prospective abstinence.
The latest project in the group of studies focused on drug
effects, ‘Opioid Efficacy in Humans’ (DA023063), recruited
81 MZ pairs and 31 DZ pairs from the TRR to participate
in a computer-controlled infusion of the mu opioid ago-
nist Alfentanil or placebo in a single occasion, randomized
cross-over study of pain sensitivity and analgesic effects
(Angst et al., 2010). In this unique study, experimental heat
and cold pressor pain models were examined both before
and after administration of Alfentanil. Analyses determined
the relative proportion of genetic and environmental factors
in pain tolerance and threshold (Angst et al., 2012) and, in a
separate analysis, subsequent analgesic and drug side effects
(Angst et al., 2012). Ruau et al. (2012) recently used a bioin-
formatics approach to identify candidate genes associated
with pain ratings of several medical conditions. A number
of identified candidates were subsequently genotyped using
DNA from twin participants who had been prospectively
assessed for experimentally induced pain phenotypes as a
step in the validation process.
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Studies Focused on the Human Immuno-
logical Response Repertoire
Mutagen sensitivity is an in-vitro short-term lymphocyte
culture assay that gauges host susceptibility by measuring
induced chromatid breaks following exposure to an array of
mutagens. A series of previous studies indicated that muta-
gen sensitivity is apromising environmentally relatedcancer
risk predictor. The assay was expanded by replacing the ini-
tial test mutagen bleomycin with 4-nitroquinoline-1-oxide
(4-NQO, an ultraviolet light [UV]mimetic agent), gamma-
radiation, and benzo(alpha)pyrene diolepoxide (BPDE, a
metabolic product of benzo(alpha)pyrene, which is a com-
ponent of tobacco smoke) to measure risk of other cancers
(Wu et al., 2006). At the time this study was conducted
(‘Genetic InfluenceonMutagenSensitivity’,CA085576), the
relative contributions of genetic and environmental factors
to indicators of mutagen sensitivity were unknown. One
hundred and forty-eight pairs of MZ twins, 57 pairs of
DZ twins, and 50 siblings were recruited from the TRR to
provide peripheral blood lymphocytes for measurement of
in-vitro mutagen sensitivity. Subsequent published reports
provided estimates for genetic and environmental influ-
ences on several markers of mutagen sensitivity (Wu et al.,
2006), genotype–phenotype correlations between mutagen
sensitivity and genetic variants in the nucleotide excision
repair pathway (Lin et al., 2007), and the heritability of
mitochondrial DNA content, a risk factor for renal cell car-
cinoma (Xing et al., 2008).
The field of immunology is currently in a state of rapid
discovery with the advent of increased understanding of the
extent towhichhuman immunological processes andmech-
anisms underlie common and rare conditions. Because the
discovery of immunological markers of disease in humans
is still in its early stages, the extent to which many of these
markers are influenced by genetic and/or environmental
sources of variation remains to be determined. The use of
the twin design is a cost-effective way to determine the rel-
ative proportion of genetic and environmental influences,
both on the occurrence of conditions of known or sus-
pected immunologic etiology as well as on biomarkers that
are either associated with or predictive of these conditions
(Krishnan et al., 2012). A series of twin studies are being
conducted with members of Stanford University Medical
School’s Institute for Immunity, Transplantation, and Infec-
tion and theHuman ImmuneMonitoring Core. As a group,
these projects utilize MZ and DZ twin pairs from the TRR
as a way to determine the relative contribution of genetic
and environmental factors to innate and adaptive immuno-
logical responses to vaccination for seasonal influenza virus
(‘Influenza Immunity: ProtectiveMechanismsAgainst Pan-
demic Respiratory Virus’, U19AI057229) and for Varicella
zoster virus (‘Vaccination and Infection: Indicators of Im-
munological Health and Responsiveness’, U19AI090019).
In the influenza vaccine study, twins of both zygosities are
recruited on a seasonal basis to receive the US Centers for
Disease Control-approved vaccine and then followed on a
repeated basis to provide blood samples for immunological
assay of markers of response. As of the date of this write-
up, 74 MZ pairs and 28 DZ pairs of a variety of ages have
participated in this protocol. In the second study, the twin
design will be used to examine sources of variability in the
response to the FDA-approved vaccine for Varicella zoster,
a viral agent with substantial morbidity and mortality out-
comes in older adults (Pickering & Leplege, 2011). For this
study, 40 MZ twin pairs over the age of 50 who have had
chicken pox in the past will be recruited to participate in a
study of the immune response to the Zostavax C© vaccine. In
addition, 10 pairs of MZ twins of age 40–49 who have had
chicken pox in the past are being recruited to participate in a
cross-sectional study designed to assess immune responses
to the naturally acquiredVaricella zoster virus. These studies
are aimed at learning more about age-related differences in
immune function. To date three pairs have completed the
cross-sectional study and five pairs the vaccine study.
A second series of studies with collaborators and support
from Stanford University’s Institute for Immunity, Trans-
plantation, and Infection have recruited 27 MZ twin pairs
who are either concordant or discordant for asthma. These
twin pairs were identified by mailed survey of the entire
TRR. Of the approximately 1,350 responses received, 76
pairs were subsequently identified and contacted for possi-
ble participation in a clinical study inwhichmedical history,
lung function measures, and blood samples were collected
for immunological assay. Thus far, 21 MZ twin pairs dis-
cordant for asthma have been examined for differences in
epigeneticmodifications of T cells, mediators of the inflam-
matory responses linked to asthma and the extent to which
such modifications are associated with exposure to second-
hand smoke (Runyon et al., 2012). Because of the successful
approach taken to identify twin pairs with and without a
history of asthma, a second, more comprehensive survey
of members of the TRR for a wide variety of conditions of
interest to immunologists will be conducted in 2012–2013.
Conclusions
As described above, biometric studies of twins continue
to provide clues with regard to genetic and environmen-
tal contributors to a wide variety of phenotypes associated
with important health outcomes. The inclusion of geno-
typic status in quantitative models of variation in MZ and
DZ twins provides insight into the amount of variation a
single gene or set of genes may contribute to the estimate
of total additive genetic influence in selected phenotypes
(Zaitlen & Kraft, 2012). The study of MZ twins discordant
for a particular trait or for an environmental exposure pro-
vides insight into epigenetic effects that may explain the
twin discordance (Bell & Spector, 2011). The TRR at SRI
International, while relatively modest in size compared to
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other, much larger population-based registries described in
this issue of Twin Research and Human Genetics, will con-
tinue to contribute to ground-breaking findings concerning
the etiologies of complex phenotypes that are not feasible
to assess on a larger scale.
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